Navigation Links
CVBT Opens Florida and Arizona Sites for Its ACORD Phase II Heart Trial
Date:2/24/2009

LAS VEGAS, Feb. 24 /PRNewswire-FirstCall/ -- CardioVascular BioTherapeutics, Inc. (OTC Bulletin Board: CVBT) announced today that two additional hospitals in the United States opened for patient enrollment for its ACORD Phase II clinical trial for the treatment of severe coronary heart disease. The sites are Florida Hospital/Cardiovascular Institute - Orlando Florida and Chandler Regional Medical Center and Mercy Gilbert Medical Center - Phoenix Arizona metropolitan area.

Mercy Hospital Fairfield (Ohio) and The Christ Hospital in Cincinnati, Ohio were first to open for enrollment in early September, and are working in collaboration to screen and treat patients in the trial. They treated their first patient in support of the trial in mid November 2008.

CVBT now has seven sites that are open for enrollment and intends to announce additional sites as they open for screening patents.

About CardioVascular BioTherapeutics

CVBT (OTCBB: CVBT) is a biopharmaceutical company developing human FGF-1 for cardiovascular diseases characterized by inadequate blood flow to a tissue or organ. In addition to the Phase II trial it is conducting in patients with severe coronary heart disease, the company has two FDA-authorized clinical trials in the areas of impaired wound healing seen in diabetics and in patients suffering from peripheral artery disease of the legs. An additional study is being conducted in patients with chronic back pain who may have perfusion defects to their spine. For more information about CardioVascular BioTherapeutics, Inc. please visit www.cvbt.com.

    Media Contact:
    Allison Caplan,
    CardioVascular BioTherapeutics, Inc.
    (702) 839-7200, acaplan@cvbt.com

    Investor Contact:
    Yvonne Johnson
    CardioVascular BioTherapeutics, Inc.
    (702) 839-7220, investorrelations@cvbt.com


'/>"/>
SOURCE CardioVascular BioTherapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. CVBT Opens Two Additional Sites for Patient Enrollment for Phase II Heart Trial
2. Meditrina Pharmaceuticals, Inc. Opens Investigational New Drug (IND) Application for Phase IIb Clinical Trial With MPI-676 in Endometriosis
3. EDICT Opens Public Comment Period for Clinical Trials Policy Recommendations
4. Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Breast Cancer
5. Medpace Opens Clinical Pharmacology Unit in Cincinnati, Ohio
6. Pilot Study Opens the Door for Avastin Use in Curative Setting for Women With Breast Cancer
7. PPD Opens Offices in Sydney, Australia; Copenhagen, Denmark; Lima, Peru; and Lisbon, Portugal
8. Global HIV Vaccine Enterprise Names Alan Bernstein as Inaugural Executive Director, Opens New Secretariat
9. New Risk Gene for Rheumatoid Arthritis and Lupus Opens Door to More Effective Treatments
10. Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2017)... , Pa. and KALAMAZOO, Mich. , Sept. ... Penn. , and OptiMed Specialty Pharmacy of ... partnership to offer a strategic hub service that expedites ... highly sought-after personal spirometer, Spiro PD 2.0, and wellness ... A spirometer is a medical device used to measure ...
(Date:9/12/2017)... and NEW YORK , Sept. 12, 2017 ... performance ratings for global supply chains, has published the first annual edition ... CSR performance of more than 20,400 companies evaluated by EcoVadis, based on ... 2015 and 2016. ... EcoVadis Global CSR Risk & Performance Index ...
(Date:9/9/2017)... WASHINGTON , Sept. 8, 2017 ... Mobile MRI Unit coming to Washington DC ... When: Tuesday, September 12 th – Monday, ... to Washington, D.C. offering free MRI brain scans to the public.Where:  ... – will be parked at 501 K Street NW, Washington, D.C.What:BTF brings ...
Breaking Medicine Technology:
(Date:9/26/2017)... ... 2017 , ... Two innovative companies are bringing to market ... is scientifically proven as well: ABAlife™. Euromed SA, a leading manufacturer of therapeutic ... with BioTherapeutics Inc. for patented technology for absiscic acid (ABA). , The ...
(Date:9/26/2017)... ... September 26, 2017 , ... ... Manufacturers, **An FDAnews Management Report**, http://www.fdanews.com/products/54648-principles-of-equipment-qualification      , The ... must prove that their equipment, operations and processes all work the way ...
(Date:9/26/2017)... (PRWEB) , ... September 26, 2017 , ... ... orthopedic surgeon and the Chair of the Leg, Ankle, and Foot Section of ... currently the only fellowship trained orthopedic surgeon at Hackensack UMC performing total ankle ...
(Date:9/26/2017)... ... September 26, 2017 , ... ... Premier Inc. Effective October 1, 2017, the new agreement allows Premier members, at ... for patient scales. , “DETECTO is pleased to renew our agreement with Premier ...
(Date:9/26/2017)... ... 26, 2017 , ... “Good Morning Sunshine!: Finding Strength and Comfort in God”: ... Sunshine!: Finding Strength and Comfort in God” is the creation of published author, Terri ... University, who has worked at a local mental health center for over twenty years, ...
Breaking Medicine News(10 mins):